Navigation Links
Lotrel, a Single-Pill Combination for Treating High Blood Pressure, Reduced Cardiovascular Events by 20% in High-Risk Patients
Date:3/31/2008

ns or labeling for Lotrel or regarding potential future revenues from Lotrel. Such forward-looking statements reflect the current views of the Company regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with Lotrel to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Lotrel will be submitted or approved for any additional indications or labeling. Nor can there be any guarantee that Lotrel will achieve any particular levels of revenue in the future. In particular, management's expectations regarding Lotrel could be affected by, among other things, the company's ability to obtain or maintain patent or other proprietary intellectual property protection, including for the Lotrel 5/40 mg and 10/40 mg capsules; unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; competition in general; government, industry and general public pricing pressures, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Novartis Pharmaceuticals Corporation researches, develops, manufactures and markets leading innovative prescription drugs used to treat a number of diseases and conditions, including those in the cardiovasc
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
2. ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
3. New 48-Week Efficacy and Safety Data Presented for INTELENCE(TM) (etravirine) as Part of HIV Combination Therapy
4. Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
5. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
6. Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
7. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
8. New Drug Combination is Able to Eradicate Breast Metastases in Mice
9. Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma
10. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Stem Cell Transplantation
11. Avicena Announces Positive Phase II Data for a Combination Trial Involving AL-08 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its Israeli ... sophisticated agro-breeding solutions for plant breeders and researchers, today ... of directors appointed chemistry and pharmaceutical industry expert Dr. ... the board. From 1975 to 2012, Dr. ...
(Date:1/15/2014)... R.I. , Jan. 15, 2014 MultiCell Technologies, ... filed a U.S. provisional patent application concerning composition of ... to achieve targeted tumor cell death.  ... small noncoding double stranded RNA molecules (VSRNAs) which interfere ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... & Forecast – Worldwide Analysis ... Pump Market Analysis ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
... Inc. (NYSE: CRY ), a leading ... surgery, announced today that it has completed its ... and markets the HeRO (Hemodialysis Reliable Outflow) Graft, ... (ESRD) hemodialysis patients with limited access options and ...
... UBM Conferences , a division of UBM Plc (LSE: ... and Leachables Webinar to be hosted on May 17th, ... attend webinar will evaluate the considerations to be made ... in addition to highlighting how monomers and additives, such ...
Cached Medicine Technology:CryoLife Completes Acquisition of Hemosphere 2CryoLife Completes Acquisition of Hemosphere 3CryoLife Completes Acquisition of Hemosphere 4Global Webinar Focuses on Considerations for Extractables and Leachables 2
(Date:4/18/2014)... online in The Gerontologist reports ... associated with a decrease in anxiety about death and ... over their lives. In particular, listening to gospel music ... and an increase in sense of control. , These ... men, and individuals of both low- and high-socioeconomic status. ...
(Date:4/18/2014)... Fraser University psychologists have made a brain-related discovery ... attention-deficit disorders. , This discovery opens up the ... or suppress a specific brain activity that the ... , The Journal of Neuroscience has ... John McDonald, an associate professor of psychology and ...
(Date:4/17/2014)... non-cancerous prostate tissue may have nearly twice the risk ... inflammation, according to results of a new study led ... , The link between persistent inflammation and cancer was ... those with a Gleason score between 7 and ... and rapidly growing prostate cancers. , "What we,ve shown ...
(Date:4/17/2014)... Experimental Biology and Medicine a multidisciplinary research ... Kenis in the Institute of Genomic Biology (IGB) ... Urbana-Champaign describe their recent work on subcellular redox ... cell functions including energy metabolism, signaling, and transcriptional ... normal cellular behavior, redox status has been recognized ...
(Date:4/17/2014)... synthetic biology team has created a new technology ... that could travel the body and selectively target ... cell-based, biological devices that monitor and modify human ... biology. However, no existing technology enabled bioengineers to ... state and respond in a customized fashion. , ...
Breaking Medicine News(10 mins):Health News:Religious music brings benefit to seniors' mental health 2Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2
... consent, many can,t recall details, study finds , WEDNESDAY, ... doctors doesn,t seem to help parents of children having ... procedures, researchers have found. , Before a child can ... what,s called informed consent. The process has four main ...
... ... Grand Opening Event Celebration at Azia Medical Spa in Birmingham, AL. , ... Birmingham, AL (PRWEB) March 17, 2010 -- Dee ... Azia Medical Spa will host a two day Grand Opening Celebration March 25 ...
... , March 17 Sleep HealthCenters has recently entered into a partnership with Milton Hospital, an affiliate ... Beginning this month, Sleep HealthCenters will perform diagnostic sleep studies at Milton Hospital with plans to open a clinic ... ... , ...
... of the pancreas is relatively rare. There are ... (PET), especially the non-functioning ones, in clinical and ... in the literature showed that the expression profiles ... in difficulty distinguishing the two entities. In recent ...
... integrated care, research shows , WEDNESDAY, March 17 (HealthDay ... them away from work can recover an average of four ... of rehabilitation program, a new study suggests. , Researchers in ... back pain who hadn,t been able to go to work ...
... Germany , March 17 Anatomist and ... Dr. Angelina Whalley present their new exhibition, ... ) , premiering at the Neunkirchen Zoo in ... holistic and sculptural anatomical menagerie, the display features the most revered ...
Cached Medicine News:Health News:Risks of Kids' Surgeries May Not Stick With Parents 2Health News:Azia Medical Spa in Birmingham, AL to Host Two Day Grand Opening Event March 25 and March 26, 2010. 2Health News:Azia Medical Spa in Birmingham, AL to Host Two Day Grand Opening Event March 25 and March 26, 2010. 3Health News:Sleep HealthCenters at Milton Hospital Now Open 2Health News:Sleep HealthCenters at Milton Hospital Now Open 3Health News:Gunther von Hagens' BODY WORLDS of Animals Opening March 19 at the Neunkirchen Zoo 2Health News:Gunther von Hagens' BODY WORLDS of Animals Opening March 19 at the Neunkirchen Zoo 3
The applicator is designed for a smooth delivery of the solution for surgical procedures....
... BioSynthetic Mesh is a ... in the central section ... film of porcine collagen. ... the Avaulta™ BioSynthetic Mesh ...
The Repliform Tissue Regeneration Matrix is an acellular human dermal allograft that when surgically implanted is intended to function as a template, facilitating the body's fibroblasts to regenerate...
... Matrix delivers the advanced performance benefits ... and durability in a safe, permanent ... site-specific defect repair in pelvic floor ... porcine dermal collagen that readily incorporates ...
Medicine Products: